Biotech,

Here Come The Biotechs

Biotech Bounce Coming?

This is an abbreviated version today.

Biotech may be getting ready to mount its comeback, based on the trading the Nasdaq Biotech ETF ($IBB). The chart below shows how the ETF is grazing up long-term trend line while appearing to be in the process of creating a double bottom.

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Get This In Your E-Mail Subscribe

 

[poll id=”8″]

Celgene

Celgene shares lead the Biotech’s into this mess, and Celgene is going to have to drive it out of this mess. The stock has two huge gaps that need to be filled, and if the stock can clear $103, it may very well be on the path to filling the first one.

Celgene

Biogen

Biogen shares may be signaling a bottom as well, with “W” type of pattern being created.

Biogen

[poll id=”9″]

Micron

Micron shares are surging again! And the options traders are back in the name as well.  With nearly 32,000 of the November 17 $46 calls trading.

micron

Tesla

Tesla once again held the 200-DMA and found a nice bounce mid-day to take the stock back to its longer-term trend line.  That is a positive for Tesla bulls.

Premium Content:

Qualcomm Has Big Problems

Facebook, Alibaba, Apple Earning Preview

What Good Are The Analyst Worth!

Dollar Breakout, Bad For Euro

GE And Celgene, Plus FAANG’s

Tech, Biotech, And Why BofA Can Go To $40

Biotech Could Falter

Free Articles Written By Mike:

Amazon, Alphabet And Microsoft Simply Crushed It

Why Mastercard’s Stock Could Rise 15%

Why Amazon’s Earnings Aren’t As Strong As They Look

Qualcomm Deal With NXP Will Eventually Get Done – M…

Celgene and Biogen May Be Signalling A Biotech Bottom

AMD Could Rise 10% Despite Results, Trades Indicate

Why Tesla’s Stock Is Breaking Down

Why Is McDonald’s Valued Like a Big Tech Stock?

Why Biogen May Sink Biotech Sector As Earnings Beat

Netflix Stock Likely to Rise as EPS Estimates Jump

Bank of America Could Rise Nearly 50%: Technical Analysis

AMD Could Break Out After Results

Qualcomm’s Bid For NXP Still Lacks Investor Support

Celgene’s Sharp Sell-Off Is Likely Overdone

Procter & Gamble Continues To Have Two Big Problems

GE: Getting Excited For The Future

Why IBM’s Big Stock Rally Won’t Last

Allergan Shares On The Verge Of Further Breakdown

We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.

-OR-

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]

Michael Kramer and the clients of Mott Capital own shares of TSLA and CELG

Photo Credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.